GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Radiant Innovation Inc (ROCO:3373) » Definitions » Debt-to-EBITDA

Radiant Innovation (ROCO:3373) Debt-to-EBITDA : 0.00 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Radiant Innovation Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Radiant Innovation's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$0.0 Mil. Radiant Innovation's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$0.0 Mil. Radiant Innovation's annualized EBITDA for the quarter that ended in Mar. 2024 was NT$-64.2 Mil. Radiant Innovation's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Radiant Innovation's Debt-to-EBITDA or its related term are showing as below:

ROCO:3373's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.26
* Ranked among companies with meaningful Debt-to-EBITDA only.

Radiant Innovation Debt-to-EBITDA Historical Data

The historical data trend for Radiant Innovation's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiant Innovation Debt-to-EBITDA Chart

Radiant Innovation Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Radiant Innovation Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Radiant Innovation's Debt-to-EBITDA

For the Medical Devices subindustry, Radiant Innovation's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiant Innovation's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Radiant Innovation's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Radiant Innovation's Debt-to-EBITDA falls into.



Radiant Innovation Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Radiant Innovation's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -43.237
=0.00

Radiant Innovation's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -64.232
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Radiant Innovation  (ROCO:3373) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Radiant Innovation Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Radiant Innovation's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiant Innovation (ROCO:3373) Business Description

Traded in Other Exchanges
N/A
Address
1F, No. 3, Industrial East 9th Rd, Science-Based Industrial Park, HsinChu, TWN, 300
Radiant Innovation Inc is engaged in the manufacture and distribution of medical instruments in Taiwan. It provides infrared ear thermometers, multi-function thermometers, infrared forehead thermometers as well as carbon dioxide detectors.

Radiant Innovation (ROCO:3373) Headlines

No Headlines